Drugs Made In America Acquisition Corp. - Ordinary share ($0.0001 par value) (DMAA)

Q: What does CUSIP G2847J104 represent in this 13F holders report?

CUSIP G2847J104 is the security identifier for DMAA - Drugs Made In America Acquisition Corp. - Ordinary share ($0.0001 par value) used to aggregate holder disclosures.

Q: How many institutions held DMAA - Drugs Made In America Acquisition Corp. - Ordinary share ($0.0001 par value) in Q2 2025?

32 institutional investors reported DMAA - Drugs Made In America Acquisition Corp. - Ordinary share ($0.0001 par value) for Q2 2025. Use the holders table for investor-level position and value details.

CUSIP: G2847J104

Q2 2025 13F Holders as of 30 Jun 2025

Security type / class: Equity / Ordinary share ($0.0001 par value)
Total 13F shares: 20,823,195
Total 13F value: $212,304,432
Share change: +3,496,868
SEC-reported price per share: $10.20
Number of holders: 32
Value change: +$35,784,995
Number of buys: 18
Number of sells: 6
Shares outstanding: 24,267,224

Security key

G2847J104

Report period

Q2 2025

Institutions

Top holders

DMAA full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2025 Drugs Made In America Acquisition Corp. SEC filings Drugs Made In America Acquisition Corp. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP G2847J104

Newer quarter: Q3 2025

Recent filing periods:

Q2 2026 Q1 2026 Q4 2025 Q3 2025

Ownership snapshot

Top reported holders of DMAA - Drugs Made In America Acquisition Corp. - Ordinary share ($0.0001 par value) (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Drugs Made In America Acq...

Disclosed value leader

Drugs Made In America Acq...

Comparable rows

11/15

Latest evidence

30 Jun 2025

13D/G 3/4/5 13F Lead comparable stake: 12% 4 rows are not safely comparable across share classes. 13D/G row: Drugs Made In America Acquisition LLC Showing 1-6 of 15 holder rows.

Quick read

Drugs Made In America Acquisition LLC leads the comparable SEC ownership view at 12%.

11 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Drugs Made In America Acquisition LLC's linked filing trail.

Comparable ownership Top 5

Drugs Made In America Acquisition... 12%

Karpus Management, Inc. 8.2%

First Trust Capital Management L.P. 6.2%

Polar Asset Management Partners Inc. 5.7%

GLAZER CAPITAL, LLC 5.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Drugs Made In America Acquisition LLC	13D/G 3/4/5 10%+ Owner 13D/G 3/4/5	12%	$42,139,127 4,188,780 shares	$0	18 Feb 2025
Karpus Management, Inc.	13D/G 13F Company 13D/G 13F	8.2%	$27,989,912 2,744,109 shares	+$4,284,765	30 Jun 2025
First Trust Capital Management L.P.	13D/G 13F Company 13D/G 13F	6.2%	$20,791,022 2,066,702 shares	$0	31 Mar 2025
Polar Asset Management Partners Inc.	13F 13D/G Company 13F 13D/G	5.7% from 13D/G	$19,285,000 3,800,000 shares mixed-class rows	—	31 Mar 2025
GLAZER CAPITAL, LLC	13F 13D/G Company 13F 13D/G	5.4% from 13D/G	$18,435,000 3,122,952 shares mixed-class rows	—	31 Mar 2025
TORONTO DOMINION BANK	13F Company 13F	9.1%	$3,466,949 2,210,100 shares	—	31 Mar 2025

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

20,823,195

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2025 vs Q1 2026 Across Filers

Q1 2026 holders

Q2 2025 holders

Holder diff

-6

Investor	Q1 2026 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2026 value	Q2 2025 value	Value change	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend